Lisuride
drugOn this page
Also known as LisuridaLisuride maleateLysuride maleateRevanil 200S-(-)-LisurideLisuride (S)(-)
Summary
Lisuride (CHEMBL157138) is a phase-3 clinical-stage small-molecule antiparkinson drug (ATC G02CB02) targeting HTR6, HTR7, and HTR1A; indicated across 4 conditions including migraine disorder and restless legs syndrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: G02CB02 (+1 more)
- Targets: 17 (HTR6, HTR7, HTR1A…)
- Indications: 4 conditions
- Clinical trials: 3
- Chemistry: 338.4 Da · C20H26N4O
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL157138 |
| Name | Lisuride |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 28864 |
| ChEBI | CHEBI:51164 |
| ATC | G02CB02, N02CA07 |
| Molecular formula | C20H26N4O |
| Molecular weight | 338.4 |
| InChIKey | BKRGVLQUQGGVSM-KBXCAEBGSA-N |
SMILES: CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
IUPAC name: 3-[(6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
Pharmacological roles (ChEBI): antiparkinson drug, serotonergic agonist, dopamine agonist, antidyskinesia agent.
Also known as: Lisurida, Lisuride, Lisuride maleate, Lysuride maleate, Revanil 200, S-(-)-Lisuride, LISURIDE, Lisuride (S)(-), lisuride
Parent form; salt/anhydrous children: CHEMBL1257128
Patent coverage: 3,322 distinct patent families (13,291 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 13,236 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| HTR6 | 5-HT6 receptor | Partial agonist | 8.1 | 0.2% | P50406 |
| HTR7 | 5-HT7 receptor | Full agonist | 9.3 | 0.8% | P34969 |
| HTR1A | 5-HT1A receptor | Full agonist | 9.8 | 0% | P08908 |
| DRD1 | D1 receptor | Partial agonist | 7.2 | 0% | P21728 |
| DRD2 | D2 receptor | Partial agonist | 9.5 | 0% | P14416 |
| DRD3 | D3 receptor | Partial agonist | 9.6 | 0% | P35462 |
| DRD4 | D4 receptor | Partial agonist | 8.3 | 0% | P21917 |
| DRD5 | D5 receptor | Partial agonist | 8.5 | 0% | P21918 |
| ADRA1A | α1A-adrenoceptor | Antagonist | 8.3 | P35348 | |
| ADRA2A | α2A-adrenoceptor | Antagonist | 10.3 | 0.1% | P08913 |
| ADRA2B | α2B-adrenoceptor | Antagonist | 9.9 | 0.2% | P18089 |
| ADRA2C | α2C-adrenoceptor | Antagonist | 9.9 | 0% | P18825 |
| HTR1B | 5-HT1B receptor | Partial agonist | 7.7 | 0.2% | P28222 |
| HTR1D | 5-HT1D receptor | Partial agonist | 9 | 0% | P28221 |
| HTR2A | 5-HT2A receptor | Partial agonist | 8.6 | 0% | P28223 |
| HTR2B | 5-HT2B receptor | Antagonist | 8.9 | 0.4% | P41595 |
| HTR2C | 5-HT2C receptor | Partial agonist | 8.3 | 0% | P28335 |
Broader ChEMBL bioactivity targets: 26 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Histamine H2 receptor, Alpha-2B adrenergic receptor, D(1A) dopamine receptor, Beta-2 adrenergic receptor, Beta-1 adrenergic receptor, 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor.
Bioactivity
ChEMBL activities: 72 potent at pChembl ≥ 5 of 74 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| DRD2 | 11 | EC50 | 0.01 | nM | CHEMBL_ACT_16879809 |
| HTR2A | 10.65 | EC50 | 0.02 | nM | CHEMBL_ACT_16879801 |
| DRD3 | 10.23 | Ki | 0.06 | nM | CHEMBL_ACT_7759665 |
| ADRA2A | 9.94 | Ki | 0.12 | nM | CHEMBL_ACT_7759593 |
| DRD3 | 9.85 | Ki | 0.14 | nM | CHEMBL_ACT_1500315 |
| DRD3 | 9.76 | IC50 | 0.17 | nM | CHEMBL_ACT_7759664 |
| ADRA2B | 9.62 | Ki | 0.24 | nM | CHEMBL_ACT_7759595 |
| P19327 | 9.57 | Ki | 0.27 | nM | CHEMBL_ACT_7761793 |
| P61169 | 9.52 | Kd | 0.3 | nM | CHEMBL_ACT_218206 |
| DRD2 | 9.52 | Ki | 0.3 | nM | CHEMBL_ACT_25917655 |
| ADRA2A | 9.51 | IC50 | 0.31 | nM | CHEMBL_ACT_7759592 |
| DRD1 | 9.47 | Ki | 0.34 | nM | CHEMBL_ACT_25553896 |
| DRD2 | 9.47 | Ki | 0.34 | nM | CHEMBL_ACT_25553901 |
| HTR1A | 9.4 | Ki | 0.4 | nM | CHEMBL_ACT_122544 |
| P61169 | 9.4 | Kd | 0.4 | nM | CHEMBL_ACT_218208 |
| P19327 | 9.33 | IC50 | 0.47 | nM | CHEMBL_ACT_7761792 |
| DRD2 | 9.3 | Ki | 0.5 | nM | CHEMBL_ACT_122542 |
| HTR1A | 9.3 | Ki | 0.5 | nM | CHEMBL_ACT_25917693 |
| ADRA2B | 9.29 | IC50 | 0.52 | nM | CHEMBL_ACT_7759594 |
| P61169 | 9.22 | Kd | 0.6 | nM | CHEMBL_ACT_218205 |
| ADRA2C | 9.2 | Ki | 0.63 | nM | CHEMBL_ACT_7759597 |
| DRD2 | 9.18 | Ki | 0.66 | nM | CHEMBL_ACT_14723046 |
| DRD2 | 9.18 | Ki | 0.66 | nM | CHEMBL_ACT_14723108 |
| DRD2 | 9.1 | Ki | 0.8 | nM | CHEMBL_ACT_469423 |
| HTR2A | 9.06 | Ki | 0.87 | nM | CHEMBL_ACT_7761797 |
| DRD2 | 9.02 | Ki | 0.95 | nM | CHEMBL_ACT_7759663 |
| HTR2B | 8.96 | Ki | 1.1 | nM | CHEMBL_ACT_25629995 |
| DRD3 | 8.77 | Ki | 1.7 | nM | CHEMBL_ACT_122543 |
| DRD3 | 8.77 | Ki | 1.7 | nM | CHEMBL_ACT_25917669 |
| ADRA2A | 8.7 | Ki | 2 | nM | CHEMBL_ACT_25917713 |
Target pathways
Aggregated over 17 target gene(s): HTR6, HTR7, HTR1A, DRD1, DRD2, DRD3, DRD4, DRD5, ADRA1A, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C.
Top Reactome pathways
25 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Signal Transduction | 12 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| Signaling by GPCR | 12 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| Class A/1 (Rhodopsin-like receptors) | 12 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| Amine ligand-binding receptors | 12 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| GPCR ligand binding | 12 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| GPCR downstream signalling | 11 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| Serotonin receptors | 8 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| G alpha (i) signalling events | 7 | ADRA2A, ADRA2B, ADRA2C, DRD3, DRD4, HTR1B, HTR1D |
| Dopamine receptors | 5 | DRD1, DRD2, DRD3, DRD4, DRD5 |
| Adrenoceptors | 4 | ADRA1A, ADRA2A, ADRA2B, ADRA2C |
| G alpha (q) signalling events | 4 | ADRA1A, HTR2A, HTR2B, HTR2C |
| G alpha (s) signalling events | 4 | DRD1, DRD5, HTR6, HTR7 |
| Hemostasis | 3 | ADRA2A, ADRA2B, ADRA2C |
| Adrenaline signalling through Alpha-2 adrenergic receptor | 3 | ADRA2A, ADRA2B, ADRA2C |
| G alpha (z) signalling events | 3 | ADRA2A, ADRA2B, ADRA2C |
| Platelet activation, signaling and aggregation | 3 | ADRA2A, ADRA2B, ADRA2C |
| Platelet Aggregation (Plug Formation) | 3 | ADRA2A, ADRA2B, ADRA2C |
| Metabolism | 2 | ADRA2A, ADRA2C |
| Integration of energy metabolism | 2 | ADRA2A, ADRA2C |
| Metabolism of proteins | 2 | ADRA2A, ADRA2C |
| Adrenaline,noradrenaline inhibits insulin secretion | 2 | ADRA2A, ADRA2C |
| Regulation of insulin secretion | 2 | ADRA2A, ADRA2C |
| Surfactant metabolism | 2 | ADRA2A, ADRA2C |
| G alpha (12/13) signalling events | 1 | ADRA1A |
| RHOBTB3 ATPase cycle | 1 | HTR7 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| signal transduction | 17 |
| G protein-coupled receptor signaling pathway | 17 |
| G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 10 |
| chemical synaptic transmission | 10 |
| G protein-coupled serotonin receptor signaling pathway | 7 |
| positive regulation of MAPK cascade | 7 |
| intracellular calcium ion homeostasis | 7 |
| response to xenobiotic stimulus | 6 |
| regulation of vasoconstriction | 5 |
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | 5 |
| behavioral response to cocaine | 5 |
| phospholipase C-activating dopamine receptor signaling pathway | 5 |
| synaptic transmission, dopaminergic | 5 |
| response to cocaine | 5 |
| positive regulation of ERK1 and ERK2 cascade | 5 |
Indications & clinical
Indications
4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| migraine disorder | 4 | MONDO:0005277 | MONDO:0005277 |
| restless legs syndrome | 3 | MONDO:0005391 | EFO:0004270 |
| Parkinson disease | 3 | MONDO:0005180 | MONDO:0005180 |
| cocaine dependence | 1 | MONDO:0005186 | EFO:0002610 |
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00367822 | PHASE3 | COMPLETED | Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS) |
| NCT00089622 | PHASE2 | COMPLETED | Lisuride Patch to Treat Parkinson’s Disease |
| NCT00000338 | PHASE1 | UNKNOWN | Infusion Laboratory: Protocol 2 (Lisuride) - 3 |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
1,083 molecules share ≥1 primary target. Top 60 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| BREXPIPRAZOLE | ChEMBL + PubChem | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| DIHYDROERGOTAMINE | ChEMBL + PubChem | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| ARIPIPRAZOLE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| CARIPRAZINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| RISPERIDONE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| CLOZAPINE | ChEMBL + PubChem | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| OLANZAPINE | ChEMBL + PubChem | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| TEGASEROD | ChEMBL + PubChem | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| IMIPRAMINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| NEFAZODONE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| AMOXAPINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| CHLORPROMAZINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| DOXEPIN | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| FLUPHENAZINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| HALOPERIDOL | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| KETANSERIN | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| LOXAPINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| MIANSERIN | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| PROMAZINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| RITANSERIN | ChEMBL | Phase 2 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR2A, HTR2C, HTR6, HTR7 |
| PALIPERIDONE | ChEMBL + PubChem | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1B, HTR1D, HTR2A, HTR2C, HTR7 |
| PRAMIPEXOLE | ChEMBL + PubChem | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR2A, HTR2B, HTR7 |
| Pyrazinamide | ChEMBL + PubChem | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| AMITRIPTYLINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6 |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| AZELASTINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| CARVEDILOL | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| ERGOTAMINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6 |
| KETOTIFEN | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HTR1B, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| QUETIAPINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| SERTINDOLE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR6 |
| THIORIDAZINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| THIOTHIXENE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| ZIPRASIDONE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| PENFLURIDOL | ChEMBL | Phase 2 | ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| SPIPERONE | ChEMBL | Phase 2 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| DESLORATADINE | ChEMBL + PubChem | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6 |
| APOMORPHINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B, HTR2C |
| ASENAPINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6 |
| BROMOCRIPTINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6 |
| CYPROHEPTADINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| EBASTINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6 |
| ILOPERIDONE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6 |
| MAPROTILINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HTR1A, HTR2A, HTR2B, HTR2C, HTR6 |
| METHYSERGIDE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| PERGOLIDE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6 |
| PIMOZIDE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6 |
| PROCHLORPERAZINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6 |
| PROMETHAZINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6 |
| SILODOSIN | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2B, HTR7 |
| SUNITINIB | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6 |
| VILAZODONE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2B, HTR6, HTR7 |
| YOHIMBINE | ChEMBL | Phase 3 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR6 |
| METERGOLINE | ChEMBL | Phase 2 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| NIGULDIPINE | ChEMBL | Phase 2 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HTR1A, HTR1B, HTR2C, HTR6, HTR7 |
| SPIRAMIDE | ChEMBL | Phase 2 | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1D, HTR2A, HTR2B, HTR6, HTR7 |
| Fidaxomicin | ChEMBL + PubChem | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C |
| Propoxyphene | ChEMBL + PubChem | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C |
| BENPERIDOL | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C |
| CABERGOLINE | ChEMBL | Phase 4 (approved) | ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2B |
Related Atlas pages
- Genes: HTR6, HTR7, HTR1A, DRD1, DRD2, DRD3, DRD4, DRD5, ADRA1A, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C
- Diseases: migraine disorder, restless legs syndrome, Parkinson disease
- Drugs: Brexpiprazole, Dihydroergotamine, Aripiprazole, Cariprazine, Risperidone, Clozapine, Olanzapine, Tegaserod, Imipramine, Nefazodone, Amoxapine, Chlorpromazine, Doxepin, Fluphenazine, Haloperidol, Ketanserin, Loxapine, Mianserin, Promazine, Paliperidone, Pramipexole, Pyrazinamide, Amitriptyline, Astemizole, Azelastine, Carvedilol, Ergotamine, Ketotifen, Quetiapine, Sertindole, Thioridazine, Thiothixene, Ziprasidone, Desloratadine, Apomorphine, Asenapine, Bromocriptine, Cyproheptadine, Ebastine, Iloperidone, Maprotiline, Methysergide, Pergolide, Pimozide, Prochlorperazine, Promethazine, Silodosin, Sunitinib, Vilazodone, Yohimbine, Fidaxomicin, Propoxyphene, Benperidol, Cabergoline